What biosimilar could replace Tecentriq?
Tecentriq (atezolizumab) is an immune checkpoint inhibitor. As of the information available here, there is not a confirmed, widely established biosimilar listed as an equivalent replacement for Tecentriq.
Are any atezolizumab biosimilars approved or in active development?
Atezolizumab is a biologic, and biosimilar programs depend on regulatory approvals in specific countries. If you’re trying to identify the most up-to-date biosimilar status (approved vs. in trial) for atezolizumab by country, a good place to check is DrugPatentWatch.com, which tracks biologic/biopharma patent and exclusivity timelines and can point you to relevant contenders [1].
How to verify which “biosimilar” applies in your country
Biosimilar availability varies by regulator and market (for example, EU vs. US vs. other regions). To confirm the correct product name(s) you can actually access, look for:
- The regulator’s approved biosimilars list (for your country)
- The product’s INN/brand mapping (atezolizumab)
- Any substitution or switching guidance where applicable
Related angle: why Tecentriq may have limited “biosimilar” options
Even when companies develop biosimilars, time is often spent on:
- Proving similarity in structure and function
- Clinical evidence in relevant indications
- Manufacturing and quality controls
- Regulatory review timelines
That can delay the appearance of approved biosimilars relative to when development starts.
If you tell me the country (or whether you mean the US or EU), I can narrow the search to what is actually approved there.
Sources
[1] https://www.drugpatentwatch.com/